InChI=1S/C27H29NO11/c1- 10- 22(31) 13(28) 6- 17(38- 10) 39- 15- 8- 27(36,16(30) 9- 29) 7- 12- 19(15) 26(35) 21- 20(24(12) 33) 23(32) 11- 4- 3- 5- 14(37- 2) 18(11) 25(21) 34/h3- 5,10,13,15,17,22,29,31,33,35- 36H,6- 9,28H2,1- 2H3/t10- ,13- ,15- ,17- ,22+,27- /m0/s1 |
AOJJSUZBOXZQNB-TZSSRYMLSA-N |
COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO |
|
Escherichia coli
(NCBI:txid562)
|
See:
PubMed
|
Escherichia coli metabolite
Any bacterial metabolite produced during a metabolic reaction in Escherichia coli.
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
(via anthracycline )
antimicrobial agent
A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
(via anthracycline antibiotic )
|
|
View more via ChEBI Ontology
(1S,3S)- 3,5,12- trihydroxy- 3- (hydroxyacetyl)- 10- methoxy- 6,11- dioxo- 1,2,3,4,6,11- hexahydrotetracen- 1- yl 3- amino- 2,3,6- trideoxy- α- L- lyxo- hexopyranoside
|
doxorubicin
|
ChemIDplus
|
doxorubicine
|
ChemIDplus
|
doxorubicinum
|
ChemIDplus
|
(1S,3S)- 3- glycoloyl- 3,5,12- trihydroxy- 10- methoxy- 6,11- dioxo- 1,2,3,4,6,11- hexahydrotetracen- 1- yl 3- amino- 2,3,6- trideoxy- α- L- lyxo- hexopyranoside
|
ChEBI
|
(8S- cis)- 10- ((3- amino- 2,3,6- trideoxy- α- L- lyxo- hexopyranosyl)oxy)- 7,8,9,10- tetrahydro- 6,8,11- trihydroxy- 8- (hydroxyacetyl)- 1- methoxy- 5,12- naphthacenedione
|
ChemIDplus
|
14-hydroxydaunomycin
|
ChemIDplus
|
14-hydroxydaunorubicine
|
ChemIDplus
|
Adriamycin
|
KEGG COMPOUND
|
Adriamycin
|
KEGG COMPOUND
|
Doxorubicin
|
KEGG COMPOUND
|
DOXORUBICIN
|
PDBeChem
|
960
|
DrugCentral
|
C01661
|
KEGG COMPOUND
|
D03899
|
KEGG DRUG
|
DB00997
|
DrugBank
|
DM2
|
PDBeChem
|
LMPK13050001
|
LIPID MAPS
|
LSM-4062
|
LINCS
|
View more database links |
23214-92-8
|
CAS Registry Number
|
KEGG COMPOUND
|
23214-92-8
|
CAS Registry Number
|
ChemIDplus
|
|